A study that evaluated a PARP inhibitor (niraparib) in males with metastatic prostate cancer found that those with a BRCA1 or BRCA2 mutation lived longer on average than those who did not have a BRCA mutation. Read the full article at the link in our bio!Reference:Smith et al. Lancet Oncol. 2022;23(3):362-373. PMID: 35131040.
Permanent link to this article: https://inheritedcancer.net/post42023/
According to a recent Phase II study, Talazoparib may benefit patients with PALB2-associated breast cancer. Findings showed that Talazoparib appeared effective and safe in certain patients with advanced disease. Read the full article at the link in our bio! Reference: Gruber et al. Nat Cancer. 2022;3(10):1181-1191. PMID: 36253484.
Permanent link to this article: https://inheritedcancer.net/post32723/
